This study will test an investigational drug, theophylline, in children with
pseudohypoparathyroidism type 1a (PHP1a). This study involves a 3 day visit to the
Vanderbilt Clinical Research Center.
Study measures will be done at baseline and during a 24h infusion of IV theophylline.
Theophylline levels will be drawn to ensure therapeutic dosing and to monitor for toxicity.
Measures include laboratory values, response to PTH infusion and resting energy expenditure.
1. Age 10 to 21 years old
2. English proficiency
3. Clinical and genetic diagnosis of PHP1a
1. Use of a PDE inhibitor in the past 30 days
2. History of a seizure disorder unrelated to hypocalcemia
3. History of a cardiac arrhythmia (not including bradycardia)
4. History of hepatic insufficiency
5. AST or ALT >2x upper limit of normal
6. Total bilirubin >1.5 x upper limit of normal (unless patient has a diagnosis of
Gilbert's syndrome and no other causes leading to hyperbilirubinemia are identified)
7. Congestive heart failure
8. Cigarette use in the past 30 days
9. Alcohol use within the past 24 hours
10. Current pregnancy
11. Untreated hypothyroidism (defined as free T4 level < 0.6 ng/dL or TSH >10 mcU/mL)
12. Active peptic ulcer disease
13. Fever >101 degrees in the past 24 hours
14. Current use of medications known to effect theophylline levels (listed below)
15. Severe sleep apnea requiring BiPAP
Drugs with clinically significant drug interactions with theophylline: